Antoni van Leeuwenhoek

Running trials

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Source

• Recruiting

  Timing of Immunotherapy in Melanoma

  NCT07696715· Source

• Recruiting

  NO Re-excision MelanomA - NORMA 2

  NCT07530887· Phase 3· Source

• Recruiting

  INTERACT Stomach-II

  NCT07133490· Phase 2· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

  NCT06855095· Phase 2/3· Source

• Recruiting

  NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

  NCT06342037· Phase 2· Source

• Recruiting

  Basket Study for Oligo-metastatic Breast Cancer

  NCT05982678· Phase 2· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Source

• Recruiting

  Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

  NCT05180864· Source

• Recruiting

  Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

  NCT07260435· Phase 3· Source

• Recruiting

  COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

  NCT05301881· Phase 2· Source

• Recruiting

  FMT to Convert Response to Immunotherapy

  NCT05251389· Phase 1/2· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Recruiting

  Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision

  NCT05772923· Source

• Recruiting

  TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  NCT04294927· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Source

• Active, not recruiting

  Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases

  NCT03413254· Phase 3· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Source

• Active, not recruiting

  Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

  NCT01792934· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Melanoma3 recruiting
• Metastatic breast cancer3 recruiting
• Childhood cancers2 recruiting
• Triple-negative breast cancer2 recruiting
• Kidney cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Improved Implant for Reconstruction Purposes After Mandibular Resection

  NCT05153733· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Source

• Completed

  Dose Individualization of Pemetrexed - IMPROVE-I

  NCT03656549· Phase 4· Source

• Completed

  18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

  NCT03564197· Source

• Completed

  Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

  NCT03126812· Phase 1/2· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Source